SIGN UP TO VIEW THE FULL ARTICLE

Receive a 90-day free trial of Celltelligence and get instant access to our full offering.

EMAIL BLASTS

Curated cell therapy industry news in your inbox multiple times each week

SEARCHABLE LIBRARY

A full archive of cell therapy news, insights, and context

THE MAP

A 24/7 information center that lets you make unique connections

The price for access is $0.00.

Do you have a discount code? Click here to enter your discount code.

Account Information

Username

Password

Confirm Password

Work E-mail Address

Confirm E-mail Address

Occupation

Other

Full Name LEAVE THIS BLANK

Payment Information We accept all major credit cards

Card Number

Expiration Date

CVC

Discount Code

I want to receive updates from celltelligence.com.

By selecting this, I agree to receive emails from celltelligence.com.

Processing...

Already have an account? Log in here

RETURN TO HOME

Allogeneic, BCMA, CAR-T, CD19

August 08, 2022

Precision's Cash Runway Extended to YE 2024; No Major Clinical Updates; Precision BioSciences Q2 2022 Earnings Call Summary

Here is a brief preview of this blast: On Monday, August 8, Precision BioSciences released their Q2 2022 earnings results (press release) highlighting PBCAR0191’s (allogeneic CD19 CAR-T) data readout in June 2022. Of note, no major updates were reported for PBCAR19B (allogeneic stealth CD19 CAR-T) or PBCAR269A (allogeneic BCMA CAR-T). Below, Celltelligence provides insights on PBCAR0191’s potential approval pathway, while discussing potential clinical delays for Precision's MM programs.

About The Author

The Celltelligence Team

Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.